Roche’s CEO claimed 89bio’s drug, which is in late-stage testing, has the potential to show “best-in-disease efficacy” for many people with the condition.Roche on Thursday agreed to acquire 89bio, wagering that a medicine the biotechnology company is developing could offer a new way to treat a common liver condition.The Swiss pharmaceutical giant will pay $14.50 […]
